Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Celcuity 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
4.31B
Market cap4.31B
Price-Earnings ratio
-20.57
Price-Earnings ratio-20.57
Dividend yield
Dividend yield
Average volume
677.05K
Average volume677.05K
High today
$89.15
High today$89.15
Low today
$87.01
Low today$87.01
Open price
$87.61
Open price$87.61
Volume
258.69K
Volume258.69K
52 Week high
$151.02
52 Week high$151.02
52 Week low
$44.42
52 Week low$44.42

Stock Snapshot

Celcuity(CELC) stock is priced at $88.17, giving the company a market capitalization of 4.31B. It carries a P/E multiple of -20.57.

On 2026-08-31, Celcuity(CELC) stock traded between a low of $87.01 and a high of $89.15. Shares are currently priced at $88.17, which is +1.3% above the low and -1.1% below the high.

The Celcuity(CELC)'s current trading volume is 258.69K, compared to an average daily volume of 677.05K.

During the past year, Celcuity(CELC) stock moved between $44.42 at its lowest and $151.02 at its peak.

During the past year, Celcuity(CELC) stock moved between $44.42 at its lowest and $151.02 at its peak.

CELC News

Simply Wall St 2d
What Could Celcuity Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st

...

What Could Celcuity Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
TipRanks 5d
Celcuity Files sNDA to Expand REVTORPYK Breast Cancer Use

The latest update is out from Celcuity ( (CELC) ). On August 26, 2026, Celcuity submitted a supplemental New Drug Application to the U.S. FDA seeking approval...

TipRanks 5d
Celcuity submits Revtorpyk sNDA to the FDA

Celcuity (CELC) announced the submission of its supplemental new drug application, or sNDA, to the FDA for Revtorpyk for the treatment of patients with hormone...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

TipRanks 7d
Celcuity Inc. Earnings Call: Revtopik Launch Set Stage

Celcuity Inc. ((CELC)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful investin...

Simply Wall St 7d
How Investors May Respond To Celcuity Deepening Losses As Gedatolisib Commercial Plans Advance

In the second quarter of 2026, Celcuity Inc. reported a net loss of US$78.86 million, or US$1.44 per share, with first-half net loss widening to US$131.71 milli...

How Investors May Respond To Celcuity Deepening Losses As Gedatolisib Commercial Plans Advance

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.